Videos / Cardiovascular benefits of GLP-1s – New evidence
Interventional Cardiologist and Clinical Trialist; Royal Adelaide Hospital, Queen Elizabeth Hospital, University of Adelaide, Victorian Heart Institute
0.5 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0.5 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
0.5 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0.5 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
Treating obesity is now recommended as part of best practice care for patients living with overweight and obesity who have had an adverse cardiovascular event. As Cardiologist Dr Adam Nelson explains, weight loss should now be considered a therapeutic target, in the same way we treat cholesterol and blood pressure, when implementing secondary prevention, such as after a heart attack. He will also present evidence for the effectiveness of GLP-1 agonists in this space and how semaglutide 2.4mg can and should be included in clinical care, according to international cardiology guidelines and even our own TGA recommendations.
Late Diagnosis Autism
Cardiovascular Risk Assessment in Lipid Management
Q&A on Heavy Menstrual Bleeding Management
Spirometry for COPD - GP Guide
Browse the latest videos from Healthed.
You have completed the Educational Activities (EA) component of this activity.
Select ‘Confirm & claim CPD‘ to confirm you have engaged with this activity in its entirety and claim your CPD.
You will be taken to explore further CPD learning available to you.